View in EDS

Mavacamten in Obstructive Hypertrophic Cardiomyopathy Patients Referred for Septal Reduction: Health Status Analysis Through Week 56 in VALOR-HCM Trial.

Saved in:
Bibliographic Details
Title: Mavacamten in Obstructive Hypertrophic Cardiomyopathy Patients Referred for Septal Reduction: Health Status Analysis Through Week 56 in VALOR-HCM Trial.
Authors: Desai, Milind Y.1,2,3 (AUTHOR) desaim2@ccf.org, Owens, Anjali4 (AUTHOR), Wolski, Kathy2,3 (AUTHOR), Geske, Jeffrey B.5 (AUTHOR), Saberi, Sara6 (AUTHOR), Wang, Andrew7 (AUTHOR), Sherrid, Mark8 (AUTHOR), Cremer, Paul C.1,2,3 (AUTHOR), Lakdawala, Neal K.9 (AUTHOR), Tower-Rader, Albree10 (AUTHOR), Fermin, David11 (AUTHOR), Naidu, Srihari S.12 (AUTHOR), Smedira, Nicholas G.1,13 (AUTHOR), Schaff, Hartzell14 (AUTHOR), McErlean, Ellen2,3 (AUTHOR), Sewell, Christina2,3 (AUTHOR), Zhong, Yue15 (AUTHOR), Wyrwich, Kathleen W.1,15 (AUTHOR), Lampl, Kathy L.15 (AUTHOR), Sehnert, Amy J.15 (AUTHOR)
Source: Journal of the American College of Cardiology (JACC). Sep2024, Vol. 84 Issue 11, p1041-1045. 5p.
Database: Academic Search Ultimate
Description
ISSN:07351097
DOI:10.1016/j.jacc.2024.06.025